DE68903077T2 - Benzopyrrolidinon-derivate, verfahren zu ihrer herstellung und arzneimittel, die sie enthalten. - Google Patents
Benzopyrrolidinon-derivate, verfahren zu ihrer herstellung und arzneimittel, die sie enthalten.Info
- Publication number
- DE68903077T2 DE68903077T2 DE8989402303T DE68903077T DE68903077T2 DE 68903077 T2 DE68903077 T2 DE 68903077T2 DE 8989402303 T DE8989402303 T DE 8989402303T DE 68903077 T DE68903077 T DE 68903077T DE 68903077 T2 DE68903077 T2 DE 68903077T2
- Authority
- DE
- Germany
- Prior art keywords
- derivatives
- carbon atoms
- atoms
- carbon
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 8
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title abstract description 4
- 238000004519 manufacturing process Methods 0.000 title description 6
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000001301 oxygen Substances 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 239000004044 bronchoconstricting agent Substances 0.000 claims abstract description 3
- 230000002741 bronchospastic effect Effects 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- -1 methylenedioxy group Chemical group 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000001555 benzenes Chemical class 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- HIJDYLLGIRHLGY-UHFFFAOYSA-N 1-[2-(4-benzhydryloxypiperidin-1-yl)ethyl]-3h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1CCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 HIJDYLLGIRHLGY-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 150000002475 indoles Chemical class 0.000 claims description 2
- 150000002518 isoindoles Chemical class 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 239000005864 Sulphur Substances 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 238000002844 melting Methods 0.000 description 24
- 230000008018 melting Effects 0.000 description 24
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 10
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960002912 fenspiride Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- OQAOREVBRZVXDS-UHFFFAOYSA-N 4-benzhydryloxypiperidine Chemical compound C1CNCCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OQAOREVBRZVXDS-UHFFFAOYSA-N 0.000 description 2
- FVNFBBAOMBJTST-UHFFFAOYSA-N 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound O1C(=O)NCC11CCN(CCC=2C=CC=CC=2)CC1 FVNFBBAOMBJTST-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229960002698 oxatomide Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WATGBFNRNGQGCB-UHFFFAOYSA-N 1-(2-bromoethyl)-3h-indol-2-one Chemical compound C1=CC=C2N(CCBr)C(=O)CC2=C1 WATGBFNRNGQGCB-UHFFFAOYSA-N 0.000 description 1
- BDATVPJWNOPRFX-UHFFFAOYSA-N 1-[2-(4-benzhydryloxypiperidin-1-yl)ethyl]-3,3-dimethylindol-2-one Chemical compound C12=CC=CC=C2C(C)(C)C(=O)N1CCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 BDATVPJWNOPRFX-UHFFFAOYSA-N 0.000 description 1
- BJGWBSBHQQAURG-UHFFFAOYSA-N 1-[2-(4-benzhydryloxypiperidin-1-yl)ethyl]-3-propan-2-yl-3h-indol-2-one Chemical compound C12=CC=CC=C2C(C(C)C)C(=O)N1CCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 BJGWBSBHQQAURG-UHFFFAOYSA-N 0.000 description 1
- YITFHKRVNHBUMH-UHFFFAOYSA-N 1-[2-(4-benzhydryloxypiperidin-1-yl)ethyl]-5-fluoro-3h-indol-2-one Chemical compound O=C1CC2=CC(F)=CC=C2N1CCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 YITFHKRVNHBUMH-UHFFFAOYSA-N 0.000 description 1
- JQUKYKTXKUHMPS-UHFFFAOYSA-N 1-[2-(4-benzhydryloxypiperidin-1-yl)ethyl]-7-fluoro-3h-indol-2-one Chemical compound C1=2C(F)=CC=CC=2CC(=O)N1CCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 JQUKYKTXKUHMPS-UHFFFAOYSA-N 0.000 description 1
- XZGQBXMXWBFBEG-UHFFFAOYSA-N 1-[2-(4-benzhydrylsulfanylpiperidin-1-yl)ethyl]-3h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1CCN(CC1)CCC1SC(C=1C=CC=CC=1)C1=CC=CC=C1 XZGQBXMXWBFBEG-UHFFFAOYSA-N 0.000 description 1
- VLNIHGSNSIDXPD-UHFFFAOYSA-N 1-[3-(4-benzhydryloxypiperidin-1-yl)propyl]-3h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1CCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 VLNIHGSNSIDXPD-UHFFFAOYSA-N 0.000 description 1
- UWZOJTWWUBBJLE-UHFFFAOYSA-N 1-[3-(4-benzhydryloxypiperidin-1-yl)propyl]-5-fluoro-3h-indol-2-one Chemical compound O=C1CC2=CC(F)=CC=C2N1CCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 UWZOJTWWUBBJLE-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003361 anti-bronchoconstrictory effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical group C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8811057A FR2635524B1 (fr) | 1988-08-19 | 1988-08-19 | Nouveaux derives de benzopyrrolidinone, leur procede de preparation et les compositions pharmaceutiques les renfermant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE68903077D1 DE68903077D1 (de) | 1992-11-05 |
| DE68903077T2 true DE68903077T2 (de) | 1993-04-29 |
Family
ID=9369428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8989402303T Expired - Fee Related DE68903077T2 (de) | 1988-08-19 | 1989-08-18 | Benzopyrrolidinon-derivate, verfahren zu ihrer herstellung und arzneimittel, die sie enthalten. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4968705A (OSRAM) |
| EP (1) | EP0356323B1 (OSRAM) |
| JP (1) | JPH02108689A (OSRAM) |
| AT (1) | ATE81126T1 (OSRAM) |
| AU (1) | AU617849B2 (OSRAM) |
| CA (1) | CA1327581C (OSRAM) |
| DE (1) | DE68903077T2 (OSRAM) |
| DK (1) | DK405589A (OSRAM) |
| ES (1) | ES2045502T3 (OSRAM) |
| FR (1) | FR2635524B1 (OSRAM) |
| GR (1) | GR3006670T3 (OSRAM) |
| IE (1) | IE64349B1 (OSRAM) |
| NZ (1) | NZ230355A (OSRAM) |
| OA (1) | OA09127A (OSRAM) |
| PT (1) | PT91485B (OSRAM) |
| ZA (1) | ZA896318B (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459151A (en) * | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
| GB2308362A (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Ltd | Pharmaceutical indole derivatives |
| JP2018525350A (ja) | 2015-07-02 | 2018-09-06 | ホライズン オルファン エルエルシー | Ａｄｏ耐性システアミン類似体およびその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2695290A (en) * | 1952-03-28 | 1954-11-23 | Hoffmann La Roche | Derivatives of indole and method for the production thereof |
| FR1545549A (fr) * | 1966-11-30 | 1968-11-08 | Hoffmann La Roche | Procédé pour la préparation de composés hétérocycliques |
| YU39992B (en) * | 1976-04-02 | 1985-06-30 | Janssen Pharmaceutica Nv | Process for obtaining new piperazine and piperidine derivatives |
| GR65270B (en) * | 1978-10-10 | 1980-07-31 | Fujisawa Pharmaceutical Co | Isatin derivatives and processes for the preparation thereof |
| US4261990A (en) * | 1979-03-09 | 1981-04-14 | Ciba-Geigy Corporation | N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics |
| US4540780A (en) * | 1983-06-02 | 1985-09-10 | Warner-Lambert Company | Diphenylmethylene piperidines |
| JPH0660160B2 (ja) * | 1985-12-13 | 1994-08-10 | テルモ株式会社 | アミド誘導体およびこれを含有する抗アレルギ−剤 |
-
1988
- 1988-08-19 FR FR8811057A patent/FR2635524B1/fr not_active Expired - Lifetime
-
1989
- 1989-08-10 US US07/391,936 patent/US4968705A/en not_active Expired - Fee Related
- 1989-08-17 DK DK405589A patent/DK405589A/da not_active Application Discontinuation
- 1989-08-18 OA OA59626A patent/OA09127A/xx unknown
- 1989-08-18 CA CA000608748A patent/CA1327581C/fr not_active Expired - Fee Related
- 1989-08-18 PT PT91485A patent/PT91485B/pt active IP Right Grant
- 1989-08-18 NZ NZ230355A patent/NZ230355A/en unknown
- 1989-08-18 JP JP1212847A patent/JPH02108689A/ja active Pending
- 1989-08-18 ES ES89402303T patent/ES2045502T3/es not_active Expired - Lifetime
- 1989-08-18 IE IE265389A patent/IE64349B1/en not_active IP Right Cessation
- 1989-08-18 DE DE8989402303T patent/DE68903077T2/de not_active Expired - Fee Related
- 1989-08-18 EP EP89402303A patent/EP0356323B1/fr not_active Expired - Lifetime
- 1989-08-18 AT AT89402303T patent/ATE81126T1/de not_active IP Right Cessation
- 1989-08-18 AU AU39984/89A patent/AU617849B2/en not_active Ceased
- 1989-08-18 ZA ZA896318A patent/ZA896318B/xx unknown
-
1992
- 1992-12-24 GR GR920403108T patent/GR3006670T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE64349B1 (en) | 1995-07-26 |
| DK405589D0 (da) | 1989-08-17 |
| PT91485A (pt) | 1990-03-08 |
| FR2635524A1 (fr) | 1990-02-23 |
| AU3998489A (en) | 1990-02-22 |
| FR2635524B1 (fr) | 1992-04-24 |
| DK405589A (da) | 1990-02-20 |
| EP0356323B1 (fr) | 1992-09-30 |
| PT91485B (pt) | 1995-05-04 |
| GR3006670T3 (OSRAM) | 1993-06-30 |
| JPH02108689A (ja) | 1990-04-20 |
| AU617849B2 (en) | 1991-12-05 |
| DE68903077D1 (de) | 1992-11-05 |
| CA1327581C (fr) | 1994-03-08 |
| OA09127A (fr) | 1991-10-31 |
| US4968705A (en) | 1990-11-06 |
| ES2045502T3 (es) | 1994-01-16 |
| ATE81126T1 (de) | 1992-10-15 |
| EP0356323A1 (fr) | 1990-02-28 |
| IE892653L (en) | 1990-02-19 |
| ZA896318B (en) | 1990-05-30 |
| NZ230355A (en) | 1991-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3433327C2 (de) | 1-Heteroaryl-4-[(2,5-pyrrolidindion-1-yl)alkyl]piperazinderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel | |
| DE69014351T2 (de) | Pyridincarbonsäureamid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen. | |
| DE68908374T2 (de) | Propenonoximether, Verfahren zu dessen Herstellung sowie diese enthaltende Arzneinmittel. | |
| DE3522604A1 (de) | Neue feste formen von 2-(gamma)thoxy-4-(n-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl)-benzoesaeure, diese formen enthaltende arzneimittel und verfahren zu ihrer herstellung | |
| DE69006872T2 (de) | 1H,3H,7-Pyrrolo [1,2-c]thiazolcarbonsäureamid-Derivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen. | |
| DE69733427T2 (de) | Tetrahydrobezindol derivate | |
| DE2305092C2 (OSRAM) | ||
| DE3329628C2 (OSRAM) | ||
| DD263772A5 (de) | Verfahren zur herstellung neuer 1h, 3h-pyrrolo[1,2-c]thiazolderivate | |
| DE69104948T2 (de) | Spiro[4,5]decanderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen. | |
| DE3781174T2 (de) | Verwendung von aromatischen diaminen fuer die behandlung von angina pectoris und diamine dafuer. | |
| DE69002338T2 (de) | Pyrrolidin-Derivate und ihre pharmazeutische Verwendung. | |
| DE3813531A1 (de) | Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate | |
| DE3854991T2 (de) | Cyclische Amine und pharmakologische Verbindungen | |
| CH642966A5 (en) | 1-(2-Chlorophenyl)-4-[2-(1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzox epin-1-yl)ethyl]piperazine and pharmacologically acceptable acid addition salts thereof | |
| DE2724478C2 (de) | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP0665228A1 (de) | Neue 3-Phenylsulfonyl-3,7-diazabicyclo(3,3,1)nonan-Verbindungen enthaltende Arzneimittel | |
| EP0072961B1 (de) | 1-Phenylindazol-3-on-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE69017265T2 (de) | Pyrrolidonderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel. | |
| DE3503074A1 (de) | Hydantoinderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten | |
| DE68905363T2 (de) | Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten. | |
| DE69424816T2 (de) | N-Benzylpiperazinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende Zusammensetzungen | |
| DE3634942A1 (de) | Neue 4-benzyl-1-(2h)-phthalazinon-derivate | |
| DE3423429A1 (de) | Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen | |
| DE3715763A1 (de) | Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |